Antimotility agent

Last updated

Antimotility agents are drugs used to alleviate the symptoms of diarrhea. These include loperamide (Imodium), bismuth subsalicylate (Pepto-Bismol), [1] diphenoxylate with atropine (Lomotil), and opiates such as paregoric, tincture of opium, codeine, and morphine. In diarrhea caused by invasive pathogens such as Salmonella , Shigella , and Campylobacter , the use of such agents has generally been strongly discouraged, though evidence is lacking that they are harmful when administered in combination with antibiotics in Clostridioides difficile cases. [2] Use of antimotility agents in children and the elderly has also been discouraged in treatment of EHEC (Shiga-like toxin producing Escherichia coli ) due to an increased rate of hemolytic uremic syndrome. [3]

Contents

Loperamide (Imodium)

Mechanism of action

Loperamide is a μ-opioid receptor agonist. [4] By binding to μ-opioid receptors, loperamide inhibits acetylcholine release and decreases excitation of neurons in the myenteric plexus, which leads to a decrease in peristalsis. [4] Decreasing intestinal motility prolongs the transit time of food content through the digestive tract, which allows for more fluid absorption; thereby alleviating diarrhea symptoms and improving stool consistency and frequency. [4]

Unlike other opiates, loperamide does not cross the blood brain barrier, so there is minimal risk for abuse. [5]

Adverse effects

Side effects of use of anti-motility agents include:

Contraindications

Contraindications include:

Drug interactions

CYP3A4 inhibitors, such as erythromycin, fluconazole, ketoconazole, quinidine, and ritonavir, increase plasma levels of loperamide. [7]

Bismuth subsalicylate (Pepto-Bismol)

Mechanism of action

Bismuth subsalicylate (BSS) has both antibacterial and anti-secretory actions that help with diarrhea. [1] Once in the gut, BSS gets broken down into bismuth and salicylic acid. [1] Bismuth produces other bismuth salts, which blocks the binding and proliferation of bacteria in stomach mucosal cells, leading to a decrease in inflammation in the intestine. [9] Also, BSS inhibits cyclooxygenase enzyme and leads to a decrease in the production of prostaglandins, which are compounds that increase intestinal inflammation and motility. [1] Lastly, this antidiarrheal agent enhances fluid reabsorption, which helps improve diarrhea symptoms and stool consistency. [1]

Adverse effects

Adverse effects include:

Contraindications

Contraindications include:

Drug interactions

Drug interactions may occur with: [1]

See also

References

  1. 1 2 3 4 5 6 7 8 9 Budisak P, Abbas M (2024). "Bismuth Subsalicylate". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID   32809532 . Retrieved 2024-04-22.
  2. Koo HL, Koo DC, Musher DM, DuPont HL (March 2009). "Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis". Clinical Infectious Diseases. 48 (5): 598–605. doi: 10.1086/596711 . PMID   19191646.
  3. Bae WK, Lee YK, Cho MS, Ma SK, Kim SW, Kim NH, et al. (June 2006). "A case of hemolytic uremic syndrome caused by Escherichia coli O104:H4". Yonsei Medical Journal. 47 (3): 437–439. doi:10.3349/ymj.2006.47.3.437. PMC   2688167 . PMID   16807997.
  4. 1 2 3 4 5 6 Schiller LR (May 2017). "Antidiarrheal Drug Therapy". Current Gastroenterology Reports. 19 (5): 18. doi:10.1007/s11894-017-0557-x. PMID   28397130.
  5. Schiller LR, Pardi DS, Sellin JH (February 2017). "Chronic Diarrhea: Diagnosis and Management". Clinical Gastroenterology and Hepatology. 15 (2): 182–193.e3. doi:10.1016/j.cgh.2016.07.028. PMID   27496381.
  6. 1 2 3 4 5 6 7 8 9 10 Forrester A (August 1, 2018). "Diarrhea" . Retrieved April 27, 2024.
  7. 1 2 Regnard C, Twycross R, Mihalyo M, Wilcock A (August 2011). "Loperamide". Journal of Pain and Symptom Management. 42 (2): 319–323. doi: 10.1016/j.jpainsymman.2011.06.001 . PMID   21703817.
  8. 1 2 3 4 Leung AK, Leung AA, Wong AH, Hon KL (2019-08-05). "Travelers' Diarrhea: A Clinical Review". Recent Patents on Inflammation & Allergy Drug Discovery. 13 (1): 38–48. doi:10.2174/1872213X13666190514105054. PMC   6751351 . PMID   31084597.
  9. O'Malley PA (March 2020). "Pink Prescribing: Bismuth Subsalicylate; History, Actions, Risks, and Future Use". Clinical Nurse Specialist. 34 (2): 45–47. doi:10.1097/NUR.0000000000000509. PMID   32068631.